Introduction
Pulsed field ablation (PFA) utilizes intermittent, high-intensity electric field for short durations (micro- or nanoseconds) to achieve cell death through irreversible electroporation.1,2,3Most unique to PFA is its tissue selectivity.4 That is, different tissues have specific characteristic threshold field strengths that induce necrosis.5 Preclinical and clinical studies have found that cardiac myocytes in general exhibit a lower threshold for irreversible electroporation as compared to phrenic nerve (PN) or esophageal tissue.6,7,8,9 In this preclinical study, we demonstrate the feasibility and safety of two novel, 8-French, 16-electrode, single-shot, bipolar, spiral PFA/mapping catheters (CRC EP, Inc, Tustin, CA).